Drug profile · INN
polatuzumab vedotin
POLIVY
polatuzumab vedotin (POLIVY) is a b-cell antigen receptor complex-associated protein beta chain binding agent.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01FX14
Patents linked 0
Pipeline programs 9
News articles 0
Drug details — polatuzumab vedotin
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 9
- Data quality
- 0.83
Quick answer
polatuzumab vedotin (POLIVY) is a b-cell antigen receptor complex-associated protein beta chain binding agent.
Key facts
INN polatuzumab vedotin
Brand POLIVY
Mechanism B-cell antigen receptor complex-associated protein beta chain binding agent
Target B-cell antigen receptor complex-associated protein beta chain
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FX14
Mechanism of action
B-cell antigen receptor complex-associated protein beta chain binding agent
Primary target: B-cell antigen receptor complex-associated protein beta chain
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is polatuzumab vedotin?
polatuzumab vedotin (POLIVY) is a b-cell antigen receptor complex-associated protein beta chain binding agent.
What is the brand name for polatuzumab vedotin?
POLIVY is a marketed brand name for polatuzumab vedotin. Check FDA Drugs@FDA for the current US label holder and prescribing information.